PPARG and synucleinopathy: Future clinical trials with PPARγ agonists, in the early stages of PD, are required to analyze their effect on clinical scales (both motor and non-motor manifestations), cabinet tests, as well as biomarkers that reflect neuroinflammation, oxidative stress, neurodegeneration, and the α-synucleinopathy.